{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:46:10Z","timestamp":1789994770141,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.ejps.2013.01.009","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T18:18:39Z","timestamp":1358965119000},"page":"726-734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer"],"prefix":"10.1016","volume":"48","author":[{"given":"Signe Beck","family":"Petersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette Gammelgaard","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik Lytt","family":"Rahbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Guldbrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Brayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2013.01.009_b0005","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1023\/A:1013330815253","article-title":"Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats","volume":"18","author":"Ahsan","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.01.009_b0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0928-0987(03)00163-5","article-title":"Effects of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodextrin, on insulin movement across human bronchial epithelial cells (16HBE14o-)","volume":"20","author":"Ahsan","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.01.009_b0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: applications and advances","volume":"14","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2013.01.009_b0020","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1023\/A:1010974909998","article-title":"Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells","volume":"18","author":"Behrens","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.01.009_b0025","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jbmr.1602","article-title":"A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial","volume":"27","author":"Binkley","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejps.2013.01.009_b0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1567201052772834","article-title":"Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery","volume":"2","author":"Cano-Cebrian","year":"2005","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejps.2013.01.009_b0035","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1208\/s12249-008-9165-2","article-title":"Preparation and characterization of salmon calcitonin-biotin conjugates","volume":"9","author":"Cetin","year":"2008","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejps.2013.01.009_b0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejps.2009.02.004","article-title":"Lipeo-sCT: a novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity","volume":"37","author":"Cheng","year":"2009","journal-title":"Eur. J. Pharm. Sci"},{"key":"10.1016\/j.ejps.2013.01.009_b0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejps.2013.01.009_b0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00198-007-0490-1","article-title":"Salmon calcitonin: a review of current and future therapeutic indications","volume":"19","author":"Chesnut","year":"2008","journal-title":"Osteoporosis Int."},{"key":"10.1016\/j.ejps.2013.01.009_b0055","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0030-1248255","article-title":"Back to the future: revisiting parathyroid hormone and calcitonin control of bone remodeling","volume":"42","author":"de Paula","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ejps.2013.01.009_b0060","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2004.12.017","article-title":"Improvement of absorption enhancing effects of n-dodecyl-beta D-maltopyranoside by its colon-specific delivery using chitosan capsules","volume":"293","author":"Fetih","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.01.009_b0240","series-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"1275","article-title":"Hormonal regulation of calcium and phosphate homeostasis","author":"Friedman","year":"2011"},{"key":"10.1016\/j.ejps.2013.01.009_b0070","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/aem.55.3.679-683.1989","article-title":"Significance of microflora in proteolysis in the colon","volume":"55","author":"Gibson","year":"1989","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.ejps.2013.01.009_b0075","doi-asserted-by":"crossref","first-page":"981","DOI":"10.4155\/tde.12.79","article-title":"Peptide therapeutics: it\u2019s all in the delivery","volume":"3","author":"Grant","year":"2012","journal-title":"Therapeut. Deliv."},{"key":"10.1016\/j.ejps.2013.01.009_b0080","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nature Protoc."},{"key":"10.1016\/j.ejps.2013.01.009_b0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jconrel.2012.01.024","article-title":"Nasal drug delivery \u2013 recent developments and future prospects","volume":"161","author":"Illum","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.01.009_b0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0378-5173(93)90363-K","article-title":"The mucus layer as a barrier to drug absorption in monolayers of human intestinal epithelial HT29-H goblet cells","volume":"99","author":"Karlsson","year":"1993","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.01.009_b0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00063030-200822030-00001","article-title":"Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality","volume":"22","author":"Karsdal","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejps.2013.01.009_b0100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/0091270010372625","article-title":"Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials","volume":"51","author":"Karsdal","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.01.009_b0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11095-004-9007-1","article-title":"In vitro and ex vivo intestinal tissue models to measure mucoadhesion of poly (methaerylate) and N-trimethylated chitosan polymers","volume":"22","author":"Keely","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.01.009_b0110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1023\/A:1015838508656","article-title":"Relationship between drug absorption enhancing activity and membrane perturbing effects of acylcarnitines","volume":"8","author":"LeCluyse","year":"1991","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.01.009_b0120","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0169-409X(00)00063-6","article-title":"Oral delivery of salmon calcitonin","volume":"42","author":"Lee","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2013.01.009_b0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.regpep.2009.12.008","article-title":"Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice. A study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration","volume":"160","author":"Lee","year":"2010","journal-title":"Regul. Peptides"},{"key":"10.1016\/j.ejps.2013.01.009_b0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.regpep.2011.02.009","article-title":"Oral delivery of octreotide acetate in Intravail\u00ab improves uptake, half-life, and bioavailability over subcutaneous administration in male swiss webster mice","volume":"167","author":"Maggio","year":"2011","journal-title":"Regul. Peptides"},{"key":"10.1016\/j.ejps.2013.01.009_b0250","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13346-012-0069-z","article-title":"High efficiency intranasal drug delivery using Intravail\u00ae alkylsaccharide absorption enhancers","volume":"3","author":"Maggio","year":"2013","journal-title":"Drug Deliv. Trans. Res"},{"key":"10.1016\/j.ejps.2013.01.009_b0135","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.ddtec.2011.11.006","article-title":"Overcoming poor permeability: translating permeation enhancers for oral peptide delivery","volume":"9","author":"Maher","year":"2012","journal-title":"Drug Discov. Today: Technol."},{"key":"10.1016\/j.ejps.2013.01.009_b0140","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.addr.2009.09.006","article-title":"Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic","volume":"61","author":"Maher","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2013.01.009_b0145","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1002\/art.22075","article-title":"Oral salmon calcitonin reduces Lequesne\u2019s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis","volume":"54","author":"Manicourt","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejps.2013.01.009_b0150","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1081\/PDT-65686","article-title":"Oral delivery of mono-PEGylated sCT (Lys18) in rats: regional difference in stability and hypocalcemic effect","volume":"10","author":"Mansoor","year":"2005","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2013.01.009_b0155","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11914-011-0084-x","article-title":"Oral calcitonin","volume":"10","author":"Maricic","year":"2012","journal-title":"Curr. Osteoporosis Rep."},{"key":"10.1016\/j.ejps.2013.01.009_b0160","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.addr.2011.10.006","article-title":"Oral colon delivery of insulin with the aid of functional adjuvants","volume":"64","author":"Maroni","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2013.01.009_b0165","unstructured":"Mehta, N., 2010. Clinical development of an oral formulation of recombinant calcitonin. The Peptide Conference 2010. <http:\/\/www.unigene.com\/wp-content\/uploads\/2011\/09\/ClinicalDevofOralsCTPresentation1.pdf>. (accessed 25.8.12)."},{"key":"10.1016\/j.ejps.2013.01.009_b0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0378-5173(92)90107-D","article-title":"Assessment of enhancing ability of medium-chain alkyl saccharides as new absorption enhancers in rat rectum","volume":"79","author":"Murakami","year":"1992","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.01.009_b0175","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.joca.2011.01.008","article-title":"Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover","volume":"19","author":"Nielsen","year":"2011","journal-title":"Osteoarthr. Cartilage"},{"key":"10.1016\/j.ejps.2013.01.009_b0255","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejps.2012.08.010","article-title":"Evaluation of alkyl maltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers","volume":"47","author":"Petersen","year":"2012","journal-title":"Eur. J. Pharm. Sci"},{"key":"10.1016\/j.ejps.2013.01.009_b0185","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jps.1111","article-title":"HT29-MTX and Caco-2\/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer","volume":"90","author":"Pontier","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.01.009_b0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2008.12.014","article-title":"Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate","volume":"135","author":"Ryan","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.01.009_b0195","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/jps.2600841120","article-title":"Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats","volume":"84","author":"Sinko","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.01.009_b0200","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2005.05.016","article-title":"Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts","volume":"106","author":"Song","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2013.01.009_b0245","unstructured":"Stern, W. and Gilligan, J. P, 1999. Oral salmon calcitonin pharmaceutical products. Unigene Laboratories Inc. USP 5,912,014."},{"key":"10.1016\/j.ejps.2013.01.009_b0210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00726-007-0532-1","article-title":"Enhancement of intestinal absorption of macromolecules by spermine in rats","volume":"33","author":"Sugita","year":"2007","journal-title":"Amino Acids (Vienna)"},{"key":"10.1016\/j.ejps.2013.01.009_b0215","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/bp0101379","article-title":"PH-Sensitive hydrogels as gastrointestinal tract absorption enhancers: transport mechanisms of salmon calcitonin and other model molecules using the Caco-2 cell model","volume":"18","author":"Torres-Lugo","year":"2002","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.ejps.2013.01.009_b0220","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.2042-7158.1997.tb06773.x","article-title":"Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon","volume":"49","author":"Tozaki","year":"1997","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2013.01.009_b0225","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/03639040903173580","article-title":"Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats","volume":"36","author":"Wu","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2013.01.009_b0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10611860400020191","article-title":"Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin","volume":"13","author":"Yang","year":"2005","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2013.01.009_b0235","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jconrel.2006.06.007","article-title":"Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy","volume":"114","author":"Youn","year":"2006","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:44:34Z","timestamp":1760528674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098713000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":47,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0928098713000365"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2013.01.009","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2013.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}